Regulation
The UK regulatory position on research peptides, in plain terms
Not a licensed medicine, not a food supplement. What that classification actually means, and where most confusion comes from.
Veritide Research · 4 August 2026 · 5 min read
Research peptides occupy an unusual position in United Kingdom law, and the confusion around that position is where much unreliable information originates. The framework itself is reasonably clear.
They are not licensed medicines
Under the Human Medicines Regulations 2012, a product may fall within the definition of a medicine partly through its presentation — what it is claimed to do. An unlicensed chemical reference material holds no MHRA marketing authorisation: no approved indication, no patient information leaflet, and no permitted health claims. Describing such a compound in terms of treating, preventing or improving a condition presents it as a medicine.
They are not food supplements
Food supplement law covers products intended for human consumption. Unlicensed reference materials are not, which is the reason research-use-only labelling exists as a legal position rather than as a formality.
Advertising rules apply regardless of classification
The Advertising Standards Authority's CAP Code governs marketing communications whatever a product's regulatory class. Claims must be substantiated and commercial relationships must be obvious. That is one reason this site carries no commercial relationships at all: an editorial reference has no product to substantiate claims about.
- Unlicensed status means no approved use exists in the United Kingdom, for people or animals.
- Published trial data from another jurisdiction do not confer UK authorisation.
- Any site publishing dosing protocols for an unlicensed compound has moved outside that framework.
Sources
Published for research and educational reference only. Not medical advice. No dosing, administration or acquisition guidance is provided.
